AR101

BIOLOGICAL7 trials

Sponsors

Aimmune Therapeutics, Inc., Regeneron Pharmaceuticals, Aimmune Therapeutics UK Limited

Conditions

Peanut Allergypeanut allergy

Phase 2

Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)

CompletedNCT03682770

Regeneron PharmaceuticalsPeanut Allergy

Start: 2018-10-03End: 2021-07-23Updated: 2024-02-07

Phase 3

PALISADE Follow-on Study (ARC004)

CompletedNCT02993107

Aimmune Therapeutics, Inc.Peanut Allergy

Start: 2016-12-29End: 2019-05-31Updated: 2022-03-17

Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children (RAMSES)

CompletedNCT03126227

Aimmune Therapeutics, Inc.Peanut Allergy

Start: 2017-05-08End: 2018-09-23Updated: 2021-11-02

Longer-term Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008)

CompletedNCT03292484

Aimmune Therapeutics, Inc.Peanut Allergy

Start: 2017-11-02End: 2023-04-27Updated: 2024-12-19

AR101 Real-World Open-Label Extension Study

CompletedNCT03337542

Aimmune Therapeutics, Inc.Peanut Allergy

Start: 2017-10-18End: 2019-09-20Updated: 2021-11-02

Real World, Open Label, QOL Assessment of Peanut Immunotherapy AR101 in Children and Adolescents

TerminatedNCT03703791

Aimmune Therapeutics, Inc.Peanut Allergy

Start: 2018-10-24End: 2018-11-23Updated: 2021-07-13

Peanut allergy oral immunotherapy study of AR101 for desensitization in children and adults (Palisade) follow-on study.

Active, not recruitingNL-OMON48551

Aimmune Therapeutics UK Limitedpeanut allergy

Start: 2017-09-22Target: 4Updated: 2024-02-28

Related Papers

Dupilumab as an Adjunct to Oral Immunotherapy in Pediatric Patients With Peanut Allergy

Allergy2024-12-1425 citations

Anaphylactic reaction requiring epinephrine in a <scp>10‐year‐old</scp> patient undergoing peanut challenge while on dupilumab therapy

Pediatric Allergy and Immunology2024-02-011 citations

Post hoc analysis examining symptom severity reduction and symptom absence during food challenges in individuals who underwent oral immunotherapy for peanut allergy: results from three trials

Allergy Asthma and Clinical Immunology2023-03-134 citations

Onset of eosinophilic esophagitis during a clinical trial program of oral immunotherapy for peanut allergy

The Journal of Allergy and Clinical Immunology In Practice2021-08-1120 citations

Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis

JAMA Dermatology2019-11-06479 citations